ALK Positive Inc. shared on LinkedIn:
“It’s official! Neladalkib has received FDA approval – and you can see what it means to our ALK – positive community.
The dancing. The cheering. The faces of people who know just how much another treatment option matters.
More research. More options. More reasons for hope.
This celebration belongs to everyone who helped make it possible:
- The patients who took part in clinical trials.
- The researchers and clinical teams.
- Our friends at Nuvalent Inc. , now part of GSK, who came to us years ago with a mouse model.
- Everyone working for progress in ALK – positive lung cancer.
There’s more to do. But today? Turn up the music and celebrate with us!
Let’s congratulate everyone involved and keeping pushing for more.
Thanks to the many friends at Nuvalent including James Porter, Henry Pelish, Christopher D. Turner, Ruth Adams, Kirsten Duncan, Josh Bergren, Jason Waters, Catherine Ross, Lauren Machos – and so many others. Your work matters.”
Oncogene Cancer Research added:
“Behind this moment are years of research and a lot of people who made it possible. Thank you to the patients who took part in clinical trials, the investigators and clinical teams who ran them, and our friends at Nuvalent Inc. who worked for years to get here.
And if you want to see what another treatment option means to people living with ALK-positive lung cancer, just look at those faces. Here’s hoping more approvals follow around the world so more people can access neladalkib.
Congratulations to everyone who helped bring neladalkib to this milestone. ALK Positive Inc., we’re turning up the music and dancing with you! Let’s dance.”
You may also be interested in:
FDA Grants Accelerated Approval to Neladalkib for ALK Positive Lung Cancer
